2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Imlunestrant: new trials by email Literature Review of Imlunestrant trials Research Report on Imlunestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer Imlunestrant, Tamoxifen, Anastrozole - Breast Neoplasms | Phase 3 | Active not recruiting | Eli Lilly and Company | 8000 | 2022-10-04 | 2026-04-02 |
| A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Imlunestrant, Exemestane, Fulvestrant - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Active not recruiting | Eli Lilly and Company | 874 | 2021-10-04 | 2026-07-22 |
Breast Neoplasms (2) · Neoplasm Metastasis (1)
Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · China (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · India (2) · Italy (2) · Japan (2) · Mexico (2) · Netherlands (2)
2023 (1)